Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06944522 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
A Phase 3 study of Parkinsons Disease (PD), sponsored by BlueRock Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
- 20
- Study locations
NCT06944522 is a Phase 3 study of Parkinsons Disease (PD) that is actively recruiting participants, run by BlueRock Therapeutics. The registered enrollment target is 102 participants, below the 114-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06944522, a Phase 3 study of Parkinsons Disease (PD), is actively recruiting participants, sponsored by BlueRock Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
Conditions Studied
Interventions
- PROCEDURE Sham surgery
- BIOLOGICAL bemdaneprocel
Study Locations (20)
Michigan
- Michigan Clinical Research Unit - Neurology - Ann Arbor
- University of Michigan Clinical Research Unit - Neurology - Ann Arbor
- Quest Research Institute - Farmington Hills
New York
- UBMD Neurology - Buffalo
- Mount Sinai West - Neurology - New York
- New York Presbyterian/Weill Cornell Medical Center - New York
Florida
- University of Miami Health System - Neurology - Miami
- USF Parkinson's Disease and Movement Disorders Center - Tampa
Massachusetts
- Tufts Medical Center - Neurology - Boston
- Beth Israel Deaconess Medical Center - Boston
Arizona
- Banner Sun Health Research Institute - Sun City
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- UCLA NeuroTranslational Research Center - Los Angeles
Colorado
- University of Colorado Hospital - Neurology Clinic - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2032-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06944522
The ClinicalTrials.gov registry entry for NCT06944522 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (11% lower). The listed sponsor is BlueRock Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 2 interventions - of which Sham surgery is the first listed.
NCT06944522 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Michigan, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT06944522 about?
NCT06944522 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease". Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
What is the current status of trial NCT06944522?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2025-06-17. Estimated completion is 2032-03.
What conditions does trial NCT06944522 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD).
What interventions are being tested in trial NCT06944522?
The interventions under investigation include: Sham surgery (PROCEDURE), bemdaneprocel (BIOLOGICAL).
Who is sponsoring clinical trial NCT06944522?
This trial is sponsored by BlueRock Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06944522 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Open-Label Safety Study of ADS-5102 in PD Patients With LID
COMPLETED · Phase 3
-
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
COMPLETED · Phase 3
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.